数据
资源
版本对比
免费注册
预约演示
免费注册
AbCellera
Continues Partnership Frenzy with
AbbVie
Antibody Discovery Pact
2022-12-15
·
BioSpace
并购
引进/卖出
AbbVie
_©
AbbVie Inc.
All rights reserved.
AbbVie
and
AbCellera
inked an antibody discovery deal to develop candidates for up to five targets in several indications, the companies announced Thursday. In response,
AbCellera
’s stock rose 6.71% in pre-market trading Thursday. Under the terms of the deal,
AbbVie
will utilize
AbCellera
’s antibody discovery and development engine and develop and commercialize any antibodies discovered during the collaboration.
AbCellera
will then be eligible for research payments, clinical and commercial milestone payments and royalties. There was little information given about the expected timeline or indications the companies plan to target. However, an
AbCellera
spokesperson told
BioSpace
its antibody discovery and development engine is "specifically designed to address the barriers of conventional discovery in order to find the optimal clinical candidate with greater precision and speed, getting to the clinic – and patients – sooner." These types of partnerships are nothing new for either company. The same spokesperson said that to date, the company has partnered with 40 leading pharmaceutical and biotechnology companies on 160-plus programs. In 2022,
AbCellera
announced new partnerships with
Rallybio
,
Atlas Venture
and
Versant Ventures
, in addition to the collaboration with
AbbVie
. The company also expanded its collaboration with
Empirico
, and its first program with
Regeneron
advanced in preclinical development, the spokesperson stated. These alliances followed many previous deals with companies both large and small, including
Moderna
,
Eli
Lilly
and
Pfizer
. The partnership frenzy began in 2016 when
AbCellera
signed contracts with
Merck
,
MassBiologics
and
Teva
, among others.
AbbVie
has also been in somewhat of a partnership and acquisition frenzy as of late. On Dec. 6, the company entered into an agreement with
HotSpot Therapeutics
to expand its immunology portfolio, and in August, it inked a small-molecule deal with
Sosei
.
AbbVie
appears to be focused not only on partnerships but also on reprioritizing its efforts and resources. In October, the company dropped an autoimmune candidate to prioritize its cash cows,
Skyrizi
,
Rinvoq
and Humira. This came one week after it paid $225 million for DJS Antibodies’
fibrotic disease
candidate and antibody discovery program. (function (w, d, s, o, f, js, fjs) { w['BioSpace-Engagement-Widget'] = o; w[o] = w[o] || function () { (w[o].q = w[o].q || []).push(arguments) }; js = d.createElement(s), fjs = d.getElementsByTagName(s)[0]; js.id = o; js.src = f; js.async = 1; fjs.parentNode.insertBefore(js, fjs); }(window, document, 'script', 'be', ' ')); be('recent', 5);
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Rallybio LLC
Empirico, Inc.
Moderna, Inc.
[+13]
适应症
Upington 病
靶点
-
药物
瑞莎珠单抗
乌帕替尼
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
全球潜力靶点及FIC产品研究调研报告
智慧芽生物医药
肿瘤领域药物开发早期热门靶点研究报告(AACR 2023-2024)
智慧芽生物医药
siRNA药物Amvuttra专利调研实务指南
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务